glp-1 agonist moa Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Glucagon‐like peptide agonists: A prospective
Description
Discover the transformative impact of GLP-1 agonists, originally a diabetes treatment, on thousands of peoples weight-loss journey.
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
This review synthesizes current evidence on pharmacokinetics, ...
A 2024 RCT found semaglutide reduced hip bone density by 2.6% and lumbar spine by 2.1% in one year
